FDA group model in R [Two-Stage / GS Designs]

posted by VStus – Poland, 2016-10-20 15:57 (3184 d 20:24 ago) – Posting: # 16745
Views: 39,473

Dear Maestro,

❝ I actually lost a bit track of this discussion and I am not exactly sure what the comparisons try to achieve?!?


I'm sorry for confusion. I accept that I for sure may understood this topic completely wrong. I just wanted to address Myttiry's issue of non-similar results between R's lm() and WinNonlin in assessment of the FDA group model 1 and 2 for unbalanced dataset.

I don't have access to SAS or WinNonlin, but I have some study reports assessed via SAS using FDA's group model 1 and 2. So, in regards to Point Estimates, 90% CIs, F and P values for:
FDA Group 1 Group*Treat #Treat:Group in my R output
FDA Group 2
- Treat #Drug in my R output
- Per(Group) # group:prd in my R output
- Subj(Group*Seq) # seq:subj in R
lm() provides same results as PROC GLM

If Russian Authorities require an additional assessment using a group model, R output should be ok. So as PHX, if PE and 90%CI are not calculated using FDA Group Model 1.

Regards,
VStus

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,684 registered users;
30 visitors (0 registered, 30 guests [including 6 identified bots]).
Forum time: 12:21 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5